Donald L Siegel MD PhD

PubMed

• 1 citations
  Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy.
  Meghan Logun, Xin Wang, Yusha Sun, Stephen J Bagley, Nannan Li
  Cell Stem Cell. 2025-02-06
• 3 citations
  Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
  Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, Stephan A Grupp, Noelle V Frey
  Nature Medicine. 2025-01-20
• 80 citations
  Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
  Stephen J Bagley, Meghan Logun, Joseph A Fraietta, Xin Wang, Arati S Desai
  Nature Medicine. 2024-05-01

Journal Articles

• Persistence of anti-desmoglein 3 IgG+ B-cell clones in pemphigus patients over years  
  Hammers, C., Chen, J., Lin, C., Kacir, S., Siegel, D.L., Payne, A.S., Stanley, J.R., J Invest Dermatol, 1/1/2014
• Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array  
  Gao, C., Liu, Y., Zhang, H., Zhang, Y., Fukuda, M.N., Palma, A.S., Kozak, R.P., Childs, R.A., Nonaka, M., Li, Z., Siegel, D.L., Hanfland, P., Peehl, D.M., Chai, W., Gr..., J Biol Chem, 1/1/2014
• The receptor for advanced glycation end products mediates lung endothelial activation by RBCs  
  Mangalmurti N.S., Friedman J.L., Wang L.C., Stolz D.B., Muthukumaran G., Siegel D.L., Schmidt A.M., Lee J.S., Albelda S.M., Am J Physiol - Lung Cell Mol Physiol, 1/1/2013
• Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus monoclonal antibody  
  Kouno M., Lin C., Schechter N., Siegel D.L., Stanley J.R., J Invest Dermatol, 1/1/2013
• Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders  
  Cines D.B., McCrae K.R., Zheng X.L., Sachais B.S., Luning Prak E., Siegel D.L., Blood, 1/1/2012
• Glypican-3-specific scFv isolation and validation for use in hepatocellular carcinoma  
  Li Y., Siegel D.L., Scholler N., Kaplan D.E., BMC Biotechnology, 1/1/2012
• Generation and validation of canine single chain Fragment variable phage display libraries  
  Braganza A., Wallace K., Pell L., Parrish C.R., Siegel D.L., Mason N.J., Veterinary Immunol & Immunopathol, 1/1/2011
• Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform  
  Zhao A., Nunez-Cruz S., Li C., Coukos G., Siegel D.L., Scholler N., J Immunol Meth, 1/1/2011
• Impact of natural infections with adeno-associated viruses on safety and efficacy of gene therapy  
  Wang L., Calcedo R., Bell P., Lin J., Grant R., Siegel D.L., Wilson J.M., Human Gene Therapy, 1/1/2011
• Anaphylactoid-like reactions in a patient with hyperLp(a)lipidemia undergoing liposorber therapy and homeotherapy with the spice turmeric  
  Adamski J., Jamensky L., Ross J., Siegel D.L., Sachais B., J Clin Apheresis, 1/1/2010
• Advanced glycation endproducts on stored erythrocytes increase endothelial reactive oxygen species generation through interaction with RAGE  
  Mangalmurti N.S., Chatterjee S., Chen G. Anderson E., Mohammed A., Siegel D.L., Schmidt A.M., Albelda S.M., Lee J.S., Transfusion, 1/1/2010
• Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen  
  Nazha A., Cook R., Vogl D.T., Mangan P.A., Gardler M., Hummel K., Cunningham K., Luger S.M., Porter D.L., Shuster S., O’Doherty U., Siegel D., Stadtmauer E.A., Bone Marrow Transplantation, 1/1/2010
• Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: Implications for targeted therapy  
  Stanley J.R., Ishii K., Siegel D.L., Payne A.S., Veterinary Dermatol, 1/1/2009
• Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma  
  Olin R.L., Vogl D.T., Porter D.L., Luger S.M., Schuster S.J., Tsai D.E., Siegel D.L., Cook R.J., Mangan P.A., Cunningham K., Stadtmauer E.A., Bone Marrow Transplantation, 1/1/2009
• Translational applications of antibody phage display  
  Siegel D.L., Immunologic Research, 1/1/2008
• Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus docorubicin, vincristine, and dexamethasone prior to high-dose melphala...  
  Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Lorem AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatsein E..., American J of Hematol, 1/1/2007
• Targeting pemphigus autoantibodies through their heavy chain variable region genes  
  Payne A.S., Siegel D.L., and Stanley J.R., J Invest Dermatol, 1/1/2007
• Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation  
  Svoboda J., Andreadis C., Elstrom R., Chong E.A., Downs L.H., Berkowitz A., Luger S.M., Porter D.L., Nasta S., Tsai D., Loren A.W., Siegel D.L., Glatstein E., Alavi A...., Bone Marrow Transplantation, 1/1/2006
• Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure  
  Kucher C., Steere J., Elenitas R., Siegel D.L., Xu X., J Amer Acad Derm, 1/1/2006
• Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display  
  Payne A.S., Ishii K., Kacir S., Lin C., Li H., Hanakawa Y., Tsunoda K., Amagai M., Stanley J.R., Siegel D.L., J Clinical Invest, 1/1/2005
• Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma  
  Andreadis C., Schuster S.J., Chong E.A., Svoboda J., Luger S.M., Porter D.L., Tsai D.E.., Nasta S.D., Elstrom R.L., Goldstein S.C., Downs L.H., Mangan P.A., Cunningha..., Bone Marrow Transplantation, 1/1/2005
• Phage-display tools for blood typing  
  Siegel D.L., Current Hematology Reports, 1/1/2005
• Developing phage display tools for use in Transfusion Medicine  
  Siegel D.L., Transfusion, 1/1/2005
• Evidence that the erythrocyte Rh-blood group glycoprotein functions as an NH4+/H+ exchanger  
  Westhoff C.M., Burd C., Siegel D.L., Foskett J.K., J Biol Chem, 1/1/2004
• Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura  
  Cines D.B., McKenzie S.E., Siegel D.L., Journal of Pediatric Hematology/Oncology, 1/1/2003
• Join now to see all

Books/Book Chapters

• The Intensive Care Unit Manual 
  Chapter: Transfusion reactions. 
  O’Doherty U., Siegel D.L.Editors: Lanken, P.N., Manaker S., Kohl B.A., Hanson C.W..Elsevier Saunders, Philadelphia, PAEdition 2nd,2014
• Bacteriophages in Health and Disease 
  Chapter: Clinical applications of phage display-derived peptides and proteins. 
  Siegel D.L.Editors: Hyman P., Abedon S..CABI Press, Cambridge, U.K.2012
• American Society for Hematology Self-Assessment Program 
  Chapter: Chapter 11, Transfusion Medicine. 
  Siegel D.L., Quillen K.Editors: Gregory S.A. and McCrae K.R..2010
• Rossi’s Principles of Transfusion Medicine 
  Chapter: Rh and LW blood group systems. 
  Westhoff C., Siegel D.L.Editors: Simon T.L., Snyder E.L., Stowell C.P., Strauss R.G..Wiley-Blackwell, New York, NYEdition 4th,2009
• American Society for Hematology Self-Assessment Program 
  Chapter: Chapter 16, Transfusion Medicine. 
  Klumpp T.T., Siegel D.L.Editors: Kahn, M.Edition 3rd,2006
• Emerging Technologies and Therapies in Transfusion Medicine 
  Chapter: Diagnostic and therapeutic applications of phage display technology. 
  Siegel D.L.Editors: Stowell C.P. and Dzik W.H..American Association of Blood Banks, Bethesda, MD2003
• Rossi’s Principles of Transfusion Medicine 
  Page 113 - 122Westhoff C., Siegel D.L. Rh and LW Blood Group SystemsEditors: Simon T.L., Dzik W.H., Snyder E.L., Stowell C.P, and Strauss R.G..Lippincott Williams & Wilkins, Philadelphia, PAEdition 3rd,2002
• Methods in Molecular Biology vol 178: Antibody Phage Display: Methods and Protocols 
  Chapter: Selecting immunoglobulins to cell-surface antigens using magnetic sorting techniques. 
  Page 219 - 226Siegel D.L.Editors: Aitken, R. and O’Brien, P.M..Humana Press, Totowa, NJ2002
• Handbook of Transfusion Medicine 
  Chapter: Pre-transfusion compatibility testing. 
  Page 107 - 114Siegel D.L.Editors: Hillyer C.D., Hillyer K.L., Strobl F.J., Jefferies L.C., and Silberstein L.E..Academic Press, San Diego, CA2002
• The Compendium 2001 
  Chapter: What's a clinically significant antibody? 
  Page 115 - 120Siegel D.L.American Association of Blood Banks, Bethesda, MD2001
• Phage Display: A Laboratory Manual 
  Chapter: Cell-surface panning of phage-display libraries. 
  Siegel D.L.Editors: Barbas C.F., Burton, D.R., Scott J.K. and Silverman G.J..Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY2001
• The Compendium 2000 
  Chapter: What's a clinically significant antibody? 
  Page 120 - 125Siegel D.L.American Association of Blood Banks, Bethesda, MD2000
• Molecular Biology in Blood Transfusion 
  Chapter: Application of molecular biology in the engineering of IV immunoglobulins. 
  Page 211 - 223Siegel D.L.Editors: Smit-Sibinga C. Th..Kluwer Academic Publishers, Boston, MA2000
• The Compendium 1999 
  Chapter: Mechanism of Rh immune globulin prophylaxis revisited. 
  Page 160 - 163Siegel D.L.American Association of Blood Banks, Bethesda, MD1999
• The Compendium 1999 
  Chapter: Understanding immunogenicity on a molecular level: New insights revealed by the Rh(D) immune response. 
  Page 393 - 396Siegel D.L.American Association of Blood Banks, Bethesda, MD1999
• Applications of Molecular Biology to Blood Transfusion Medicine 
  Chapter: New Approaches to Monoclonal Antibody Production. 
  Page 73 - 102Siegel D.L.Editors: Garratty G..American Association of Blood Banks, Bethesda, MD1997
• Antibody Engineering II 
  Chapter: Isolation of cell surface-specific human monoclonal antibodies using phage display and magnetically-activated cell sorting. 
  Page 263 - 272Siegel D.L. and Chang TEditors: Hori, W.Biomedical Library Series, IBC, Boston, MA1997
• Antibody Engineering: New Technologies, Applications, & Commercialization. 
  Chapter: Identification of tumor antigens using antibody phage display. 
  Herlyn D., Pereira S., Maruyama H., Van Belle P. Elder D., Jacob L., Somasundaram R., Wallack M., and Siegel D.L.Editors: Thibeault, C.Biomedical Library Series, IBC, Boston, MA1996
• Scientific Basis of Transfusion Medicine: Implications for Clinical Practice 
  Chapter: Red blood cell autoantibodies. 
  Siegel D.L. and Silberstein L.E.Editors: Ness P. and Anderson K.W.B. Saunders Co., Philadelphia, PA1994
• Immunobiology of Transfusion Medicine 
  Chapter: Structural analyses of red blood cell autoantibodies. 
  Siegel D.L. and Silberstein L.E.Editors: Garratty, G..Marcel Dekker, New York, NY1994
• Protein Blood Group Antigens of the Human Red Cell: Structure, Function, and Clinical Significance 
  Chapter: Red cell antigen specificities and autoimmune hemolytic anemias. 
  Siegel D.L., Silberstein L.E.Editors: Agre, P. and Cartron, J.P..Johns Hopkins University Press, Baltimore, MD1992
• Current Diagnosis 8 
  Chapter: Acquired hemolytic anemia. 
  Siegel D.L., Silberstein L.E.Editors: Conn, R.B..W.B. Saunders Co., Philadelphia, PA1990
• Methods in Hematology, Volume 19 
  Chapter: Electron microscopy of red cell cytoskeletal proteins. 
  Branton D., Siegel D.L.Editors: Shohet, S.B. and Mohandas, N..Churchill-Livingston, New York, NY1988
• Join now to see all

Abstracts/Posters

• Successful red blood cell gemotyping from leukoreduced packed red blood cell segments.
  Azzato E., Gentile C., Carpenter H., Siegel D., Watt C., Annual Meeting of the Association for Molecular Pathology, National Harbor, MD, 1/1/2014
• Stem cell mobilization with Plerixafor + G-CSF in comparison to cyclophosphamide + G-CSF and time-to-progression after autologous stem cell transplantation for multipl...
  Garfall A.L., Dougherty A.L., Vogl D.T., Weiss B.W., Cohen A.D., Mangan P.A., O’Doherty U., Siegel D.L., Porter D.L., Stadtmauer E.A., Blood, 1/1/2013
• Deuterium-hydrogen exchange coupled with mass spectrometry revealed a novel autoantibody binding epitope and substrate recognition site in ADAMTS13 protease.
  Casina V., Wenbing H., Hanby H., Siegel D.L., Mayne L., Englander S.W., Zheng X.L., Blood, 1/1/2013
• Prospective monitoring of cryoprecipitate resulting in decreased product waste.
  Azzato E., Carpenter H., Miszczanczuk M., Dinh L-H., DeMuth F., Magee D., Aqui N., Siegel D., Sachais B.S., Transfusion, 1/1/2013
• Transfusions modulate the host inflammatory response and prime the endothelium for subsequent injury through the receptor for advanced glycation end products.
  Mangalmurti N.S., Qing D., Siegel D., Lee J.S., Worthen G.S., Albelda S.M., Transfusion, 1/1/2013
• Banked red cells induce Receptor for Advanced Glycation End products (RAGE) expression on lung endothelium and mediate vascular activation through RAGE.
  Mangalmurti N.S., Friedman J.L., Siegel D.L., Lee J.S., Albelda S.M., Blood, 1/1/2012
• Banked RBCs induce the expression of the receptor for advanced glycation endproducts (RAGE) on lung endothelial cells.
  Mangalmurti N.S., Friedman J.L., Wang L.C., Sun J., Siegel D.L., Lee J.S., Albelda S.M., American Thoracic Society International Conference, 1/1/2012
• Modifying the heavy chain third complementarity determining regions (H-CDR3) of pemphigus antibody to prevent pathogenicity but not binding suggests a novel approach t...
  Yamagami J., Payne A.S., Kacir S., Ishii K., Siegel D.L., Stanley J.R., J Invest Dermatol, 1/1/2010
• Developing a mouse model for antibody-mediated thrombotic thrombocytopenic purpura using antibody phage display.
  Yunk L., Ostertag E., Thiboutot M., Kacir S., Bdeir K., Siegel D.L., 12th Annual Phage Display of Antibodies and Peptides, PEGS Protein Engineering Summit, Boston, MA, 1/1/2010
• Tolerance to mature but not precursor desmoglein 1 (Dsg1) in non-pemphigus patients: implications for development of autoimmunity.
  Yamagami J., Kacir S., Payne A.S., Siegel D.L., Stanley J.R., J Invest Dermatol, 1/1/2009
• Pathogenic pemphigus foliaceus (PF) and vulgaris (PV) antibodies share a consensus amino acid motif in their CDR3 regions.
  Yamagami J., Ishii K., Payne A.S., Kacir S., Amagai M., Siegel D.L., Stanley J.R., J Invest Dermatol, 1/1/2008
• Novel method for epidermal drug delivery with non-pathogenic monoclonal pemphigus antibodies.
  Stanley J.R., Lin C., Siegel D.L., J Invest Dermatol, 1/1/2007
• Isolation of pathogenic pemphigus foliaceus (PF) monoclonal antibodies (mAbs) using an innovative phage display approach, “non-pathogenic epitope blocking”.
  Ishii K., Siegel D.L., Stanley J.R., J Invest Dermatol, 1/1/2007
• Novel method for epidermal drug delivery with non-pathogenic monoclonal pemphigus antibodies.
  Stanley J.R., Lin C., Siegel D.L., 68th Annual Meeting for the Society for Investigative Dermatology, Los Angeles, CA, 1/1/2007
• Low-density lipoprotein apheresis in an adolescent with a genetic form of steroid-resistant focal segmental glomerulosclerosis and familial combined hyperlipidemia.
  Baliff J.P., Adamski J., Berkoski L., Eisenmann C., Milone M.C., O’Doherty U., Aqui N.A., Sachais B.S., Siegel D.L., J Clin Apheresis; 28th Annual Meeting of the American Society for Apheresis, Nashville, TN, 1/1/2007
• Extensive AAV epidemiological study identifies a novel AAV variant with low seroprevalence.
  Calcedo R., Vandenberghe L.H., Lin J., Gao G.-P., Limberis M., Siegel D., Cleveland M., Auricchio A., Price M., Cleveland N., Steenssens L., Backhouse J., Moschou-Para..., 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA, 1/1/2007
• Inhibitory ADAMTS13 monoclonal autoantibodies cloned from TTP patients show restricted gene usage, inhibit murine ADAMTS13, and are blocked by rabbit anti-idiotypic an...
  Siegel D.L., Ostertag E.M., Blood, 1/1/2006
• Rational strategies for antibody targeted therapy in pemphigus vulgaris (PV).
  Payne A.S., Siegel D.L., Stanley J.R., J Invest Dermatol, 1/1/2006
• Genetic restriction of anti-desmoglein (Dsg) 1 antibodies in pemphigus foliaceus (PF).
  Ishii K., Li H., Lin C., Kacir S., Amagai M., Siegel D.L., Stanley J.R., J Invest Dermatol, 1/1/2006
• Cloning of inhibitory ADAMTS13 monoclonal autoantibodies from a TTP patient using phage display and their use to create a mouse model of acquired ADAMTS13 deficiency.
  Ostertag E.M., Siegel D.L., J Clin Apheresis, 1/1/2006
• Prognostic value of FDG-PET in lymphoma patients undergoing autologous stem cell transplantation.
  Svoboda J., Elstrom R., Chong E.A., Andreadis C., Berkowitz A., Luger S.M., Porter D.L., Nasta S., Downs L.H., Siegel D.L., Glatstein E., Alavi A., Stadtmauer E.A., Sc..., Blood, 1/1/2005
• Thalidomide and dexamethasone induction therapy is associated with superior progression-free survival after autotransplant for myeloma.
  Vogl D.T., Luger S., Porter D.L., Chong E.A., Schuster S.J. Tsai D.E., Perl A., Loren A., Goldstein S., Nasta S.D., Andreadis,C., Mangan P.A., Hummel K., Siegel D.L., ..., Blood, 1/1/2005
• Second autologous stem cell transplant (ASCT) as salvage therapy for relapsed multiple myeloma.
  Olin R.L., Porter D.L., Luger S.M., Schuster S.J., Tsai D., Nasta S., Perl A., Loren A.W., Goldstein S., Glastein E., Siegel D.L., Vogl D.T., Mangan P., Cunnigham K., ..., Blood, 1/1/2005
• Cloning inhibitory ADAMTS13 monoclonal autoantibodies from a TTP patient using phage display. (Plenary Session Abstract)
  Ostertag E.M., Kacir S., Gulendran G., Ai J., Smith P., Zheng X.L., Siegel D.L., Transfusion, 1/1/2005
• Isolation and characterization of human monoclonal antibodies (mAbs) from a pemphigus vulgaris (PV) patient by phage display.
  Payne A.S., Ishii K., Kacir, S., Lin C., Li H., Hanakawa Y., Tsunoda K., Amagai M., Siegel D.L., Stanley J.R., J Invest Dermatol, 1/1/2005
• Join now to see all

Lectures

• High-Performance Hematology: Elite Athletes and Weekend Warriors 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• High-Performance Hematology: Elite Athletes and Weekend Warriors 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Update on Hematopoietic Stem Cell Transplantation 
  San Diego, CA - 1/1/2014
• The Evolving Role of Cell Therapies 
  San Diego, CA - 1/1/2014
• Cell Harvest, Bone Marrow Transplantation, Advanced Cell Uses, Graft-v-Host Disease 
  San Diego, CA - 1/1/2014
• Engineering Apheresis-Derived T Cells to Treat Cancer 
  San Francisco, CA - 1/1/2014
• Medullary Thyroid Cancer and (Very) Personalized Medicine 
  Scripps Research Institute, La Jolla, CA - 1/1/2014
• Personalized Drugs of the Future: Apheresis Medicine-enhanced Gene and Cell Therapy 
  National Harbor, MD - 1/1/2014
• Phage Display, Metastatic Cancer, and (Very) Personalized Medicine 
  Ipswitch, MA - 1/1/2014
• Facility Considerations: Video Presentation from U Penn 
  Philadelphia, PA - 1/1/2014
• Immunobiology of Thrombotic Thrombocytopenic Purpura (TTP) 
  Washington University School of Medicine, St. Louis, MO - 1/1/2013
• The Evolving Roles of Transfusion Medicine and Cellular Engineering for Hematologic Disorders 
  1/1/2013
• Clinical Vaccine Production Facility at the Hospital of the University of Pennsylvania: Bench to Bedside in an Existing Hospital 
  Orlando, FL - 1/1/2013
• Phage Display Approaches for Devising New Translational Affinity Moieties for Drug Targeting 
  Philadelphia, PA - 1/1/2013
• Developing Novel Therapies for TTP, Plenary Session 
  Atlanta, GA - 1/1/2012
• Transfusion Medicine Physicians Career Development and Networking Dinner, Featured Speaker 
  Boston, MA - 1/1/2012
• Use of Phage Display for Developing Blood Bank Reagents and for Understanding Autoimmune Disorders Relevant to Transfusion Medicine. 
  Bethesda, MD - 1/1/2011
• Phage Display Technology: Application to the Study of Human Autoimmune Disorders. 
  University of Pennsylvania School of Medicine, Philadelphia, PA - 1/1/2011
• The Evolving Roles of Apheresis and Transfusion Medicine in Cellular Therapies. Plenary Session 
  Scottsdale, AZ - 1/1/2011
• The Expanding Role of Pathologists in Personalized Medicine and Therapeutics. 
  Robert Wood Johnson Medical School, New Brunswick, NJ - 1/1/2011
• Hit and Run Gene/Cell Therapy Protocol for HIV Using Zinc Finger Endonucleases 
  San Diego, CA - 1/1/2011
• The Evolving Roles of Apheresis and Transfusion Medicine in Cellular Therapies 
  Lake Zurich, IL - 1/1/2011
• The Expanding Role of Transfusion Medicine in Personalized Medicine and Therapeutics 
  University of Washington School of Medicine. Seattle, WA - 1/1/2011
• Phage Display. 
  SUNY Downstate Medical Center, Brooklyn, NY - 1/1/2010
• TTP: New Developments in Understanding Its Pathophysiology and in Designing More Effective Therapies. 
  Brown University, Providence, RI - 1/1/2010
• Join now to see all

Other

• Methods for Isolation of Antibody Binding to Cells. 
  Siegel D.L., United States Patent Office, #8,623,594 B2
  1/7/2014
• Drug Delivery to Human Tissues by Single Chain Variable Region Antibody Fragments Cloned by Phage Display. 
  Stanley J.R., Amagai M., Siegel D.L., United States Patent Office, #8,470,323 B2
  1/25/2013
• Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture. 
  Siegel D.L., United States Patent Office, #8,586,293 B2
  1/19/2013
• Anti-Autoimmune Antibodies for Treatment of Pemphigus. 
  Payne A.S., Siegel D.L., Stanley J.R., United States Patent Office, #8,298,545 B2
  1/30/2012
• The Expanding Role of Transfusion Medicine in Personalized Medicine and Therapeutics 
  Siegel D.L., Ortho On-Demand Webinar series: Transfusion Medicine -- What’s New and What’s Next
  1/1/2012
• Compositions, Methods and Kits Relating to Anti-Platelet Autoantibodies and Inhibitors Thereof. 
  Siegel D.L., Japanese Patent Office, #4660189
  1/7/2011
• The Evolving Role of Apheresis in Cellular Therapies, Highlights of the 2011 ASFA Meeting 
  Siegel D.L.
  1/1/2011
• Compositions and Methods for Detection of Antibody Binding to Cells. 
  Siegel D.L., United States Patent Office #7,709,219 B2
  1/4/2010
• Compositions, Methods, and Kits Relating to Anti-Platelet Autoantibodies and Inhibitors Thereof. 
  Siegel D.L., Australian Patent Office #2003251791
  1/26/2009
• Cellular Vaccine Development as Cancer Therapy 
  Siegel D.L., ReachMD Sirius/XM Radio 160
  1/1/2009
• Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture 
  Siegel D.L., European Patent Office granted, #03754675.1-2403
  1/1/2008
• Chilean Teen Gets Life-Saving Treatment at Penn 
  Siegel D.L., WPVI Health News
  1/1/2006
• Method of Agglutinating Cells. 
  Siegel D.L., European PCT application filed in 9 countries, patent number EP0935754
  1/7/2004
• LDL-Apheresis for Hyperlipidemic Disorders 
  Siegel D.L., ABC News
  1/1/2004
• Firm to Automate Typing of Blood 
  Siegel D.L., Philadelphia Business Journal
  1/1/2004
• Rh(D)-Binding Proteins and Magnetically Activated Cell Sorting Method for Production Thereof. 
  Siegel D.L., United States Patent Office #6,255,455
  1/3/2001
• Panning Phage Display Libraries. 
  Siegel D.L., Australian Patent Office #722978
  1/30/2000
• Composition and Methods for Detection of Antibody Binding to Cells-I. 
  Siegel D.L., United States Patent Office #5,985,543
  1/16/1999
• Magnetically Activated Cell Sorting for Production of Proteins. 
  Siegel D.L., United States Patent Office #5,876,925
  1/2/1999
• Phage Display: A New Technology for Producing Recombinant Human Antibodies for Rh Blood Typing. 
  Siegel D.L., American Society for Clinical Pathology (ASCP) Teleconference
  1/1/1999
• Making Strides in the Laboratory 
  Siegel D.L., Main Line Today
  1/1/1998
• Composition and Methods for Detection of Antibody Binding to Cells. 
  Siegel D.L., Australian Patent Office #732758
  1/10/1997
• Phage-Displayed Antibodies for Diagnosis and Therapy. (Video) 
  Siegel D.L., American Science Update, Science Technology Network, NY
  1/1/1997
• New approaches for preventing and treating hemolytic disease of the newborn. Live Telephone Interview 
  Siegel D.L., Health and Fitness Show with Ellen Ratner, WCHF Radio (AM 1390), Washington, DC
  1/1/1997
• Amphipathic Microcarriers. 
  Siegel D.L., United States Patent Office #4,415,668
  1/15/1983
• Join now to see all